Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)

The summary for the Focused Technology Research and Development (R01 - Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Focused Technology Research and Development (R01 - Clinical Trial Not Allowed): This initiative will support projects that focus solely on development of technologies with the potential to enable acquisition of basic biomedical knowledge. Projects should be justified in terms of technical innovation, and utility for future biomedical impact. The products of this research will be functioning prototype instruments, methods, synthetic approaches, biological products, etc., characterized adequately to be ready for first application to the type of biomedical research questions that provide the rationale for their development, but application of the proposed technology to specific biomedical questions is considered beyond the scope of the program, should not be included, and would not be funded. Proof of principle for the technology will have already been shown, but there will still be significant fundamental technical challenges. Applications should include preliminary data. Projects that have significant remaining risk but are supported by early feasibility studies might be appropriate for a three year R01 proposal with reduced budget to better manage risk and investment. Projects that are well supported by feasibility studies and propose to develop fully functional prototypes might require higher budgets and a four year duration (five years for early stage investigators). Projects that primarily focus on optimization, hardening, or obvious extrapolations of established technology might be less competitive.

Federal Grant Title:	Focused Technology Research and Development (R01 - Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-19-253
Type of Funding:	Grant
CFDA Numbers:	93.213, 93.859
CFDA Descriptions:	Information not provided
Current Application Deadline:	May 7th, 2022
Original Application Deadline:	May 7th, 2022
Posted Date:	April 12th, 2019
Creation Date:	April 12th, 2019
Archive Date:	June 12th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	April 12th, 2019

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-19-253.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Agi...; • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required); • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...; • Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01...; • Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clin...; • Probiotics for Pediatric Illnesses; • Cam Practitioner Research Education Project Grant Partnership; • Complementary and Alternative Medicine Career Transition Award (K22)
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...